Corporate Milestone

2016

Nov
AbGenomics Holding Ltd. founded in the Cayman Islands.
Aug
AbGenomics obtains FDA approval to conduct the Phase 1 clinical trial for AbGn-107 as a treatment for pancreatic, gastric and colorectal cancers.
Jan
AbGenomics demonstrated the proof of initial efficacy in a Phase-2a clinical trial study of AbGn-168H in patients with psoriatic arthritis.

2015

Mar
The Phase 1b clinical trial for AbGn-168H in aGvHD received approval from the FDA and was led by Stanford Health Care.
Feb
AbGn-168H’s phase-II clinical trial completed in the United States. The trial used an intravenous injection with a different cohort of patients.

2014

Nov
Phase-2a clinical trial for the use of AbGn-168H in treating psoriasis arthritis approved by the FDA and initiated.
Feb
Phase 2a clinical trial for AbGn-168H completed in the U.S.

2013

Dec
AbGenomics developed AbGn-107, an antibody drug conjugate to treat cancer, and applied for a patent from the USPTO. AbGn-107 enriched the AbGenomics’ pipeline and was a new drug for the global market.

2012

Aug
A Phase 2a clinical trial for AbGn-168H (targeting psoriasis) received approval from the FDA to initiate trial in the U.S.

2011

Nov
Boehringer Ingelheim completed the Phase 1 clinical trial study of AbGn-168H. A single dose intravenous injection was given to healthy male volunteers in Germany.
May
Boehringer Ingelheim was approved by the EU to conduct Phase 1 clinical trial of AbGn-168 to treat psoriasis. The trial used intravenous injection to deliver a single dose in healthy male volunteers.

2010

Oct
Boehringer Ingelheim was approved by the FDA to conduct further Phase 1 clinical trials of AbGn-168 to treat psoriasis. This trial tested an intravenous injection with a single dose and was conducted in the United States and Germany.

2008

Nov
Boehringer Ingelheim was approved by the FDA to conduct a Phase 1 clinical trial of AbGn-168 to treat psoriasis.
Feb
AbGenomics Cooperatief U.A. founded AbGenomics B.V. (AbGBV) in the Netherlands and founded AbGenomics B.V. Taiwan Branch (AbGBVTW) to continue investments in R&D resources in Taiwan.

2007

Dec
AbGCV founded AbGenomics Cooperatief U.A. (AbGCOOP) in the Netherlands to comply with the new drug licensing agreements in the European Union.
Nov
BioAlliance C.V. established in the Netherlands by AbGUS in order to obtain international patents.

2006

Jun
AbGenomics International Inc. (AbGUS) formed in the United States to exchange information and handle licensing negotiations as well as strategic cooperation between North American pharmaceutical and biotech companies.

2005

May
Boehringer Ingelheim and AbGenomics corporation signed a license agreement for the “Therapeutic Monoclonal Antibody-168”.

2003

Jun
AbGenomics developed a monoclonal antibody treatment for colorectal cancer--AbGn-7. Proof of efficacy established through animal testing. AbGenomics filed a patent application with the USPTO.

2002

Jan
AbGenomics developed AbGn-168, a monoclonal antibody treatment for multiple immune diseases and filed a patent application with the USPTO.

2001

Mar
AbGenomics developed AbProtTM, AbScreenTM for DNA vaccines. The RNA molecules induce antibody immune responses.

2000

Jun
AbGenomics founded.